Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for ...
Nurix Therapeutics, Inc. is a publicly traded biotechnology company listed on the Nasdaq under the symbol NRIX. Founded in 2009 and headquartered at 1600 Sierra Point Parkway in Brisbane, California, the company operates as a clinical-stage biopharmaceutical developer rather than as a commercial pharmaceutical manufacturer. Its central scientific strategy is ...Nurix Therapeutics, Inc. is a publicly traded biotechnology company listed on the Nasdaq under the symbol NRIX. Founded in 2009 and headquartered at 1600 Sierra Point Parkway in Brisbane, California, the company operates as a clinical-stage biopharmaceutical developer rather than as a commercial pharmaceutical manufacturer. Its central scientific strategy is targeted protein degradation, an approach intended to remove selected disease-related proteins from cells instead of merely blocking their activity. Nurix combines degrader chemistry with biological insights involving E3 ubiquitin ligases, which are cellular components that can be harnessed to mark unwanted proteins for destruction.
The company’s principal programs are focused on oncology and immune-mediated disease. NX-5948 is an orally bioavailable Bruton’s tyrosine kinase, or BTK, degrader being evaluated in Phase 2 clinical trials for relapsed or refractory B-cell malignancies and autoimmune diseases. NX-2127 is another oral BTK degrader in Phase 1a/1b development for relapsed or refractory B-cell malignancies. NX-1607 is an orally bioavailable inhibitor of Casitas B-lineage lymphoma proto-oncogene-B, commonly called CBL-B, and is being studied in Phase 1a/1b trials for immuno-oncology applications. Nurix has also been developing NX-0479, also referenced as GS-6791, an IRAK4 degrader intended for rheumatoid arthritis and other inflammatory conditions.
Nurix’s business model is research- and development-intensive. Costs are primarily associated with laboratory research, medicinal chemistry, preclinical studies, clinical-trial operations, manufacturing and testing of investigational products, regulatory activities, intellectual property, and personnel. As a clinical-stage company, it does not yet have a broad marketed-product revenue base. The supplied trailing-twelve-month data show approximately $317 million in free-cash-flow use, a negative net margin, and research-and-development expense equal to more than nine times reported revenue, illustrating the high cost of advancing a pipeline before commercial launch. In this context, conventional manufacturing bill-of-materials, or BOM, analysis is less relevant than clinical supply costs, contract research organization spending, drug-substance and drug-product production, quality control, and trial enrollment expenses.
The company has established strategic collaboration arrangements involving major pharmaceutical partners, including Gilead Sciences, Sanofi, and Pfizer, for the co-development and co-commercialization of multiple drug candidates. These relationships can provide funding, scientific resources, development expertise, and potential commercialization infrastructure, while also creating obligations to share economics and meet development milestones. Arthur T. Sands, M.D., Ph.D., has served as chief executive officer and a director since September 2014. Nurix reported 317 full-time employees, placing it in the 201-500 employee category. Its principal strategic objective is to establish targeted protein degradation and degrader-based medicines as important treatment options in cancer, autoimmune disease, and inflammatory disorders. Key risks include clinical-trial failure, regulatory setbacks, competition, dependence on collaboration partners, financing needs, manufacturing complexity, and the uncertainty inherent in bringing first-in-class medicines to market.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$84.0M
+54.0%
+44.6%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-264.5M
-36.6%
-2.7%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+77.5%
+125.3%
+104.6%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-340.2%
+12.9%
+29.6%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-314.9%
+11.3%
+29.0%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-263.5M
-44.9%
-35.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-313.7%
+5.9%
+6.7%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
10.3%
+92.6%
+18.4%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
7.02x
+8.6%
+5.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
